Award

Aging and the immune system in cardiac arrest

Description: More than 350,000 out-of-hospital cardiac arrests (OHCA) occur annually in the United States. In the absence of established treatments for post-cardiac arrest (CA) brain injury, even successfully resuscitated patients often die from brain injury or survive with severe neurological (neuro) impairment. Aging is an independent risk factor for poor outcomes after CA. With advancing age, the immune system undergoes characteristic alterations, most prominently "inflammaging," a oligoclonic state of immune dysfunction marked by elevated circulating cytokines and the accumulation of senescent cells. However the contribution of inflammaging to outcomes after CA remains undefined. In preliminary studies using single-cell RNA sequencing (sc-RNA seq) of peripheral blood mononuclear cells (PBMC), we discovered that GZMK+ CD8+ T cells were significantly reduced in patients with poor neuro outcomes. Granzyme K (GzmK) is best known as a cytotoxic protease that eliminates malignant or infected cells, but it also exerts extracellular inflammatory effects. Notably, prior studies report that GZMK+ CD8+ T cells clonally expand in older adults, suggesting a role in age-associated immune remodeling. Strikingly, in our mouse models, Gzmk-deficient mice exhibited worse survival, greater neurological injury after CA, revealing a previously unrecognized neuroprotective role for GzmK. The goal of this project is to define age-associated immunoregulatory axes that modulate systemic inflammation and brain injury after CA. Our central hypothesis is that GzmK regulates brain inflammation and mitigates neurological injury in aged patients following OHCA. To test this, we will: (1) analyze PBMC from our OHCA biobank spanning a broad age range using multiomic single-cell analysis to define age-associated immune signatures, and (2) test the role of granzyme K, a prominent part of "inflammaging" in murine cardiac arrest. This project will establish how inflammaging shapes the immune response to CA and identify GzmK as a candidate biomarker and therapeutic target. By elucidating immunological mechanisms that underlie poor neurological outcomes, this work directly supports the AHA mission to improve survival and neurological recovery from cardiovascular disease.
Amount: $168,600
Funding type: fellowship
Funder scheme: Postdoctoral Fellowship
Start date: 2026-01-01
End date: 2027-12-31
Investigator: Kohei Yamada (lead)
Institutions: Brigham and Women's Hospital, Brigham and Women's Hospital, Inc.
Field: Medicine
Funded outputs count: 0
Funder award ID: 26POST1556697
OpenAlex ID: G6056080928